Literature DB >> 7688351

Sequential process of blood-borne lung metastases of spontaneous mammary carcinoma in C3H mice.

T Sugino1, T Kawaguchi, T Suzuki.   

Abstract

We examined the correlation between growth characteristics and the incidence of lung metastases of spontaneous mammary tumors in C3H mice. The growth pattern of the mammary tumors was composed of initial rapid growth, declining growth, and further exponential growth (re-growth). The "re-growth" was closely associated with loss of differentiation and progressive increase of the incidence of lung metastases. In addition, we observed the sequential process of blood-borne lung metastases. The findings involved (i) "passive" intravasation: carcinoma nests encased in newly formed endothelial cells are released into sinusoidal vessels within primary tumors; (ii) "mechanical" arrest and proliferation of multicellular tumor emboli in pulmonary arterioles; (iii) "active" extravasation: carcinoma cells rushed out to the lung parenchyma through the arteriolar walls ruptured by initial minimal penetration of carcinoma cells and intravascular pressure. The results indicate a stable progression in the natural history of C3H mouse mammary carcinomas characterized by growth characteristics, the incidence of lung metastases, and histological change generating a poorly differentiated clone which can successfully complete a sequential process of blood-borne lung metastasis.

Entities:  

Mesh:

Year:  1993        PMID: 7688351     DOI: 10.1002/ijc.2910550125

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  9 in total

Review 1.  New paradigm for vessel intravasation by tumor cells.

Authors:  Noel Weidner
Journal:  Am J Pathol       Date:  2002-06       Impact factor: 4.307

2.  Identification of S100A14 as a metastasis-promoting molecule in a murine organotropic metastasis model.

Authors:  Takashi Sugino; Naoki Ichikawa-Tomikawa; Mizuko Tanaka; Namiko Shishito; Tomiko Miura; Masato Abe; Koji Muramatsu; Takuma Oishi; Yuko Kakuda; Takuya Kawata; Yasuto Akiyama
Journal:  Clin Exp Metastasis       Date:  2019-07-01       Impact factor: 5.150

3.  The secretory leukocyte protease inhibitor (SLPI) suppresses cancer cell invasion but promotes blood-borne metastasis via an invasion-independent pathway.

Authors:  T Sugino; T Yamaguchi; G Ogura; T Kusakabe; S Goodison; Y Homma; T Suzuki
Journal:  J Pathol       Date:  2007-06       Impact factor: 7.996

4.  Tumor cell motility and metastasis : Autocrine motility factor as an example of ecto/exoenzyme cytokines.

Authors:  S Silletti; S Paku; A Raz
Journal:  Pathol Oncol Res       Date:  1997-09       Impact factor: 3.201

5.  An invasion-independent pathway of blood-borne metastasis: a new murine mammary tumor model.

Authors:  Takashi Sugino; Takashi Kusakabe; Nobuo Hoshi; Tomiko Yamaguchi; Takanori Kawaguchi; Steve Goodison; Masayuki Sekimata; Yoshimi Homma; Toshimitsu Suzuki
Journal:  Am J Pathol       Date:  2002-06       Impact factor: 4.307

Review 6.  Tumor cell intravasation.

Authors:  Serena P H Chiang; Ramon M Cabrera; Jeffrey E Segall
Journal:  Am J Physiol Cell Physiol       Date:  2016-04-13       Impact factor: 4.249

7.  Inducing apoptosis in rolling cancer cells: a combined therapy with aspirin and immobilized TRAIL and E-selectin.

Authors:  Kuldeepsinh Rana; Cynthia A Reinhart-King; Michael R King
Journal:  Mol Pharm       Date:  2012-07-02       Impact factor: 4.939

Review 8.  The Roles of Stroma-Derived Chemokine in Different Stages of Cancer Metastases.

Authors:  Shahid Hussain; Bo Peng; Mathew Cherian; Jonathan W Song; Dinesh K Ahirwar; Ramesh K Ganju
Journal:  Front Immunol       Date:  2020-12-22       Impact factor: 7.561

9.  Morphological evidence for an invasion-independent metastasis pathway exists in multiple human cancers.

Authors:  Takashi Sugino; Tomiko Yamaguchi; Go Ogura; Atsuko Saito; Takeaki Hashimoto; Nobuo Hoshi; Sayaka Yoshida; Steve Goodison; Toshimitsu Suzuki
Journal:  BMC Med       Date:  2004-04-05       Impact factor: 8.775

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.